Related Experiment Video
Updated: Aug 10, 2026
A Protocol for Phage Display and Affinity Selection Using Recombinant Protein Baits
Published on: February 16, 2014
[Phage-display technology and its application to experimental oncological therapy]
Jan Borysowski1, Andrzej Górski
1Zakład Immunologii Klinicznej Instytutu Transplantologii Akademii Medycznej w Warszawie. wieslawa_lojek@poczta.onet.pl
Abstract:
One of the biggest challenges facing modern oncology is that of delivering drugs selectively to cancer cells and tumor endothelial cells. To achieve this goal, one can use peptides binding certain molecules on these cells. The most often used method of creating such peptides is phage-display. Peptides obtained from phage display technology can exert anti-cancer effect by inhibiting angiogenesis, decreasing tumor metastatic activity, or inhibiting enzymes important for neoplastic cell spread. They can also be used as components of antitumor vaccines or vehicles delivering cytokines, chemotherapeutics, or anti-sense oligonucleotides to tumors. Phage display technology has also enabled the development of anti-cancer recombinant antibodies, most often used as scFv molecules. ScFv-s can be further modified to increase their affinity and avidity. They can also be conjugated with molecules inducing different anti-cancer effector functions.
Insights
Phage display technology creates targeted peptides and antibodies for cancer therapy. These molecules selectively target cancer cells, inhibiting tumor growth and spread for improved oncology treatments.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Context:
- Selective drug delivery to cancer cells and tumor vasculature is a major challenge in oncology.
- Peptide-based targeting ligands offer a strategy to enhance drug specificity.
- Phage display is a key technology for identifying and developing these targeting peptides.
Purpose:
- To explore the application of phage display technology in developing targeted cancer therapies.
- To highlight the potential of phage-derived peptides and antibodies in oncology.
- To discuss the mechanisms by which these molecules exert anti-cancer effects.
Summary:
- Phage display technology is instrumental in generating peptides that bind specifically to cancer cells and tumor endothelial cells.
- These peptides can inhibit angiogenesis, reduce metastasis, and block enzymes crucial for cancer progression.
- The technology also facilitates the development of anti-cancer recombinant antibodies, such as single-chain variable fragments (scFv), for therapeutic applications.
- Modified scFv molecules can exhibit enhanced affinity and avidity, and can be conjugated with effector molecules to induce anti-cancer functions.
Impact:
- Phage display provides a powerful platform for discovering novel anti-cancer agents.
- Targeted delivery using phage-derived molecules can improve the efficacy and reduce the side effects of cancer treatments.
- This technology contributes to the development of advanced cancer vaccines and drug delivery systems.
